

**Licensing Contact:** Michael Shmilovich; (301) 435-5019; shmilovm@mail.nih.gov.

Available for licensing and commercial development is a radio-frequency coil design suitable for detecting time domain electron paramagnetic resonance responses from spin probes after pulsed excitation using radio-frequency irradiation (60–400 MHz). The coil is configured in an array of numerous surface coils of appropriate diameters connected in a parallel configuration with appropriate spacing between individual surface coils to form a volume type resonator. The design can accommodate and irradiate objects of varying dimensions, such as living objects, containing free radical spin probes and induce an EPR signal which can also be recovered by the resonator. Such a resonator has the capability of facilitating the enhanced dissipation of noise to thermal noise levels associated with the input power from the radio-frequency pulse, and recovering weak and rapidly decaying free induction decays. In addition, the lowering of the Q values by over-coupling, instead of resistively damping provides enhanced B1 fields thereby increasing the sensitivity of detection of the resonance signals after pulsed excitation.

Dated: August 2, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-18621 Filed 8-13-04; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing

to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

#### Diagnostic Tool for Diagnosing Benign Versus Malignant Thyroid Lesions

Steven Libutti *et al.* (NCI)

U.S. Provisional Application No. 60/560,900 filed 09 Apr 2004 (DHHS Reference No. E-124-2004/0-US-01)

**Licensing Contact:** Mojdeh Bahar; 301/435-2950; baharm@mail.nih.gov.

The present invention is directed to the use of genes differentially expressed in benign and malignant thyroid lesions for the diagnosis and staging of thyroid cancer. The invention allows for the analysis of RNA isolated from tissues using gene expression profiling. The invention has identified a group of genes which can be used as a diagnostic predictor model for differentiating benign versus malignant thyroid tissue using microarray or quantitative RT-PCR.

#### Pharmacodynamic Assay

Eun Joo Chung and Jane Trepel (NCI)

U.S. Provisional Application No. 60/548,894 filed 27 Feb 2004 (DHHS Reference No. E-094-2004/0-US-01)

**Licensing Contact:** Mojdeh Bahar; 301/435-2950; baharm@mail.nih.gov.

This invention is a rapid, simple, sensitive flow cytometric assay for the pharmacodynamic analysis of histone deacetylase inhibitors in clinical development as novel anti-cancer agents. The assay can be performed on 50 microliters of whole blood, the equivalent of a finger stick. The assay can quantify simultaneously the effects of multiple classes of drug and thus be used for pharmacodynamic analysis of HDAC inhibitors in combination therapy.

#### Adduct Compounds of Pyrrolobenzodiazepinones, Compositions Comprising the Same and Methods Related Thereto

Paul S. Liu (NCI), Gregory Turner, Babu R. Vishnuvajjala (NCI), David Thurston (EM), and Philip W. Howard (EM)

U.S. Provisional Application No. 60/513,751 filed 22 Oct 2003 (DHHS Reference No. E-007-2004/0-US-01)

**Licensing Contact:** Brenda Hefti; 301/435-4632; heftib@mail.nih.gov.

This invention is a small molecule that has potential as a cancer

therapeutic, termed SJG-136. It is a dimeric synthetic analog of the pyrrolobenzodiazepine family of anti-tumor antibiotics derived from various *Streptomyces* species. SJG-136 has shown significant cytotoxicity and antitumor activity *in vitro* and *in vivo*. The particular compositions disclosed in the present application represent new structures that were not claimed previously.

Dated: August 6, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-18622 Filed 8-13-04; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the National Diabetes and Digestive and Kidney Diseases Advisory Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Diabetes and Digestive and Kidney Diseases Advisory Council.

**Date:** September 22–23, 2004.

**Open:** September 22, 2004, 8:30 a.m. to 12 p.m.

**Agenda:** To present the Director's Report and other scientific presentations.

**Place:** National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

**Closed:** September 23, 2004, 9:45 a.m. to 10:15 a.m.